SEHK:9969Biotechs
A Look At InnoCare Pharma (SEHK:9969) Valuation As Dermatology Trials For Soficitinib Progress
InnoCare Pharma (SEHK:9969) has drawn fresh investor attention after dosing the first patient in a Phase II/III trial of TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across multiple late stage dermatology programs.
See our latest analysis for InnoCare Pharma.
The new dermatology trial news comes after a mixed price patch, with a 7.71% 1 month share price return and a 1 year total shareholder return of 63.92%, even though the 90 day share price return shows...